GE HealthCare & Vanderbilt publish data on AI models predicting patient response to immunotherapy

The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center utilizing artificial intelligence to enable safer and more precise cancer immunotherapies show that the models they developed predict patient responses with 70% to 80% accuracy.

Data haul improves immunotherapy response prediction

Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.

Clinical trial shows efficacy for atezolizumab combined with carboplatin

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

Nanoparticles boost anti-cancer immunity

An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

Couple’s gift helps support immunotherapy research

Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.